dc.contributor.author | Walker, A. S. | |
dc.contributor.author | Ssali, F. | |
dc.contributor.author | Ford, D. | |
dc.contributor.author | Gilks, C. F. | |
dc.contributor.author | Reid, A. | |
dc.contributor.author | Katabira, E. | |
dc.contributor.author | Grosskurth, H. | |
dc.contributor.author | Mugyenyi, P. | |
dc.contributor.author | Hakim, J. | |
dc.contributor.author | Darbyshire, J. H. | |
dc.contributor.author | Gibb, D. M. | |
dc.contributor.author | Babiker, A. G. | |
dc.date.accessioned | 2012-02-01T15:24:42Z | |
dc.date.available | 2012-02-01T15:24:42Z | |
dc.date.issued | 2010-03-29 | |
dc.identifier.citation | Walker, A.S., Ssali, F., Ford, D., Gilks, C.F., Reid, A., Katabira, E.T., Grosskurth, H., Mugyenyi, P., Hakim,J., Darbyshire, J.H., Gibb, D.M., Babiker, A.G. (2010). Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. The Lancet, 8 | en_US |
dc.identifier.issn | 0140-6736 | |
dc.identifier.uri | DOI:10.1016/S0140-6736(10)60057-8 | |
dc.identifier.uri | http://hdl.handle.net/10570/373 | |
dc.description.abstract | Background: Co-trimoxazole prophylaxis can reduce mortality from untreated HIV infection in Africa; whether benefits occur alongside combination antiretroviral therapy (ART) is unclear. We estimated the effect of prophylaxis after ART initiation in adults. Methods: Participants in our observational analysis were from the DART randomised trial of management strategies in HIV-infected, symptomatic, previously untreated African adults starting triple-drug ART with CD4 counts lower than 200 cells per μL. Co-trimoxazole prophylaxis was not routinely used or randomly allocated, but was variably prescribed by clinicians. We estimated effects on clinical outcomes, CD4 cell count, and body-mass index (BMI) using marginal structural models to adjust for time-dependent confounding by indication. DART was registered, number ISRCTN13968779. Findings: 3179 participants contributed 14 214 years of follow-up (8128 [57%] person-years on co-trimoxazole). Time-dependent predictors of co-trimoxazole use were current CD4 cell count, haemoglobin concentration, BMI, and previous WHO stage 3 or 4 events on ART. Present prophylaxis significantly reduced mortality (odds ratio 0.65, 95% CI 0.50–0.85; p=0.001). Mortality risk reduction on ART was substantial to 12 weeks (0.41, 0.27–0.65), sustained from 12–72 weeks (0.56, 0.37–0.86), but not evident subsequently (0.96, 0.63–1.45; heterogeneity p=0.02). Variation in mortality reduction was not accounted for by time on co-trimoxazole or current CD4 cell count. Prophylaxis reduced frequency of malaria (0.74, 0.63–0.88; p=0.0005), an effect that was maintained with time, but we observed no effect on new WHO stage 4 events (0.86, 0.69–1.07; p=0.17), CD4 cell count (difference vs non-users, –3 cells per μL [–12 to 6]; p=0.50), or BMI (difference vs non-users, –0.04 kg/m2 [–0.20 to 0.13); p=0.68]. Interpretation: Our results reinforce WHO guidelines and provide strong motivation for provision of co-trimoxazole prophylaxis for at least 72 weeks for all adults starting combination ART in Africa. | en_US |
dc.description.sponsorship | UK Medical Research Council, the UK Department for International Development, the Rockefeller Foundation, GlaxoSmithKline, Gilead Sciences, Boehringer-Ingelheim, and Abbott Laboratories. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.subject | Malaria | en_US |
dc.subject | HIV/AIDS | en_US |
dc.subject | HIV-infected persons | en_US |
dc.subject | Mortality | en_US |
dc.subject | CD4 cell count | en_US |
dc.subject | Haemoglobin concentration | en_US |
dc.subject | Antiretroviral therapy (ART) | en_US |
dc.title | Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort | en_US |
dc.type | Journal article, peer reviewed | en_US |